Reply to: Comment on: Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia.

Autor: Gotti G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.; Pediatric Hematology-Oncology, University of Milano-Bicocca, MBBM Foundation, Monza, Italy., Stevenson K; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Kay-Green S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, Massachusetts, USA., Blonquist TM; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Mantagos JS; Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, USA., Silverman LB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, Massachusetts, USA., Place AE; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Jan; Vol. 70 (1), pp. e29833. Date of Electronic Publication: 2022 Jul 07.
DOI: 10.1002/pbc.29833
Databáze: MEDLINE
Externí odkaz: